On the contrary, a systematic review on mortality, as well as cardiovascular and kidney statuses in patients with T2DM treated with GLP-1RAs concluded that there was no increase in the incidence of severe hypoglycaemia, pancreatitis, or pancreatic cancer (222)
[DOI] [PMC free article] [PubMed] [Google Scholar] 54.Pozzilli P., Norwood P., Jodar E., Davies M.J., Ivanyi T., Jiang H
Novo Nordisk, the Danish company that manufactures Ozempic and Wegovy, declined to comment on clinical trials involving children younger than 12
Researchers are particularly interested in 1 type of drug, glucagon-like peptide 1 receptor agonists (GLP-1 RAs), because of its promising potential in addressing the limitations of non-pharmacologic treatments
Its often said that medications dont work in the long term without lifestyle changes and indeed, clinical trials of these meds always include diet and exercise education [intermountainhealthcare.org]